March 31, 2017
FDA warnes African Viagra’s possible harmful ingredient
The Food and Drug Administration (FDA) has advised consumers not to purchase or use African Viagra, a product promoted for sexual enhancement.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
March 31, 2017
AstraZeneca wins FDA’s full approval for its lung cancer drug
U.S. Food and Drug Administration (FDA) has granted regular approval to AstraZeneca’s osimertinib (Tagrisso), for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC).
March 31, 2017
CARB-X funds Tetraphase Pharmaceuticals antibiotic research with $4M
Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance, will fund research of Tetraphase Pharmaceuticals’s pipeline candidate TP-6076, a novel, synthetic, fluorocycline antibiotic candidate with $4 million.
March 31, 2017
Canadian cannabis company Invictus MD starts trading on TSX
Invictus MD Strategies Corp.,Canada’s cannabis company, said Thursday it will move its shares from the Canadian Securities Exchange and be listed on TSX Venture Exchange, where it starts trading on March 31, 2017.
March 30, 2017
Horizon Pharma issues notice of allowance from USPTO for its anti-inflammatory drug
Horizon Pharma, a biopharmaceutical company focused identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, has issued a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number 15/180,173…
March 30, 2017
Mylan bags global rights to ColdEeze
Mylan has acquired the global rights to the Cold-Eeze brand cold remedy line from ProPhase Labs, Inc.
March 30, 2017
GSK’s new CEO gets short-term win from generic Advair delay
GlaxoSmithKline’s new CEO Emma Walmsley, who takes over on April 1, has won a short-term reprieve from the threat of generic Advair with a delay in U.S. approval for Mylan’s copy of the blockbuster lung inhaler.
March 30, 2017
FDA accepts Novartis’s BLA for acute lymphoblastic leukemia treatment
US Food and Drug Administration (FDA) has accepted the Novertis’s Biologics License Application (BLA) filing and granted priority review for CTL019 (tisagenlecleucel-T), an investigational chimeric antigen receptor T cell (CAR-T) therapy, in relapsed and refractory (r/r) pediatric and young adult patients with B-cell acute lymphoblastic leukemia (ALL).
March 29, 2017
Roche’s subsidiary Genentech wins FDA approval for MS and PPMS
U.S. Food and Drug Administration (FDA) has approved Roche’s subsidiary Genentech’s Ocrevus (ocrelizumab) to treat adult patients with relapsing forms of multiple sclerosis (MS) and primary progressive multiple sclerosis (PPMS).
March 28, 2017
The Parker Institute for Cancer Immunotherapy, BMS, CRI join to fight cancer
The Parker Institute for Cancer Immunotherapy, Bristol-Myers Squibb Company and the Cancer Research Institute (CRI) have entered into a multi-year clinical research collaboration to coordinate and rapidly initiate clinical Immuno-Oncology (I-O) studies across the Parker Institute and CRI networks.